Front line treatment of elderly multiple myeloma in the era of novel agents.
Melphalan combined with prednisone (MP) has long been the historical treatment of reference for a large proportion of elderly myeloma (MM) patients ineligible for autologous stem cell transplantation, and is still the backbone of new regimens that include the new era of novel agents. Melphalan-prednisone-thalidomide (MPT) and melphalan-prednisone-bortezomib (Velcade((R)), MPV), proved superior to MP, currently appear to be the treatments of choice for this population. In the near future melphalan-prednisone-lenalidomide (Revlimid((R)), MPR) will also provide a third therapeutic option (MPT, MPV, and MPR), in elderly multiple myeloma, eventually. These options could lead to more personalized treatment approaches, based on patient comorbidities, as the three novel agents have somewhat different toxicity profiles. Dexamethasone-based regimen is another option and questions regarding the relative efficacy of melphalan-based versus low-dose dexamethasone-based regimens will require randomized phase III trials. More intensive approaches with new drug combinations or with the incorporation of polyethylene glycolated (PEGylated) liposomal doxorubicin will also require additional studies. Additionally, the important issue of maintenance treatment needs to be further investigated. These new and emerging therapies offer multiple effective treatment options for MM patients and greatly enhanced treatment strategies for clinicians.
Venon
Marie-Dominique
MD
Service des Maladies du Sang, Hopital Huriez, CHRU, Lille, France.
Roccaro
Aldo M
AM
Gay
Julie
J
Moreau
Anne-Sophie
AS
Dulery
Remy
R
Facon
Thierry
T
Ghobrial
Irene M
IM
Leleu
Xavier
X
Blood. 2006 Feb 15;107(4):1292-8
16174762
Blood. 2008 Apr 15;111(8):4039-47
18268097
Leuk Lymphoma. 2003 Sep;44(9):1545-8
14565658
N Engl J Med. 2006 Mar 9;354(10):1021-30
16525139
Blood. 2002 May 1;99(9):3163-8
11964279
CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30
15661684
J Clin Oncol. 1998 Feb;16(2):593-602
9469347
J Clin Oncol. 1998 Dec;16(12):3832-42
9850028
J Clin Oncol. 2006 Sep 20;24(27):4507-14
16940275
J Clin Oncol. 2002 Nov 1;20(21):4319-23
12409330
Blood. 1992 Aug 15;80(4):887-90
1498331
Crit Rev Oncol Hematol. 2005 Dec;56(3):397-406
16310372
N Engl J Med. 1996 Jul 11;335(2):91-7
8649495
Eur J Haematol. 2005 Nov;75(5):370-5
16191085
Br J Haematol. 2005 Jun;129(6):763-70
15953002
N Engl J Med. 2003 Jun 26;348(26):2609-17
12826635
JAMA. 1969 Jun 2;208(9):1680-5
5818682
N Engl J Med. 2005 Jun 16;352(24):2487-98
15958804
Blood. 2001 Jul 15;98(2):492-4
11435324
Haematologica. 2006 Jul;91(7):968-71
16757414
Blood. 2008 Oct 15;112(8):3107-14
18505783
Clin Ther. 2003 Feb;25(2):342-95
12749503
N Engl J Med. 2004 Oct 28;351(18):1860-73
15509819
Br J Haematol. 2004 Oct;127(2):159-64
15461621
Blood. 1996 Apr 1;87(7):2675-82
8639883
Br J Cancer. 1988 Jan;57(1):94-9
3279997
Cancer. 2008 Apr 1;112(7):1522-8
18278812
Blood. 2008 Feb 15;111(4):1805-10
17875806
Cancer. 1975 Oct;36(4):1192-201
1175123
Blood. 2005 Dec 15;106(13):4050-3
16118317
Biochem Pharmacol. 2000 Jun 15;59(12):1489-99
10799645
J Clin Oncol. 2006 Feb 20;24(6):937-44
16418495
Ann N Y Acad Sci. 2007 Nov;1117:209-57
18056045
Br J Haematol. 2001 Sep;114(3):600-7
11552985
Bone Marrow Transplant. 2006 Feb;37(4):367-72
16415893
J Clin Oncol. 2007 Jun 10;25(17):2464-72
17515569
Lancet. 2006 Mar 11;367(9513):825-31
16530576
N Engl J Med. 1997 Jun 5;336(23):1657-64
9171069
Blood. 2006 Nov 15;108(10):3289-94
16873668
Blood. 2002 Nov 1;100(9):3063-7
12384400
Blood. 2001 Sep 1;98(5):1614-5
11520815
J Clin Oncol. 2004 Aug 15;22(16):3212-4
15249587
J Clin Oncol. 2006 Jan 20;24(3):431-6
16365178
Ann Oncol. 2008 Jun;19 Suppl 4:iv54-5
18519405
Ann Oncol. 2005 Apr;16(4):634-9
15741226
Mayo Clin Proc. 2004 Jul;79(7):875-82
15244383
Ann Oncol. 2000 Nov;11(11):1427-36
11142483
Clin Adv Hematol Oncol. 2004 Apr;2(4):233-41
16163188
Neurology. 2004 Jun 22;62(12):2291-3
15210898
Blood. 2003 Mar 15;101(6):2377-80
12424198
Lancet. 2007 Oct 6;370(9594):1209-18
17920916
Mayo Clin Proc. 2006 Aug;81(8):1047-53
16901028
Leukemia. 2008 Feb;22(2):414-23
18094721
N Engl J Med. 1999 Nov 18;341(21):1565-71
10564685
Bone Marrow Transplant. 2003 Sep;32(6):587-92
12953131
Br J Haematol. 2007 Jan;136(2):203-11
17233817
Eur J Cancer. 2007 Jan;43(2):258-70
17182241
Haematologica. 2008 Apr;93(4):560-5
18322252
Cancer. 2008 Apr 15;112(8):1754-64
18300230
Best Pract Res Clin Haematol. 2007 Dec;20(4):817-35
18070721
Blood. 2002 Jun 15;99(12):4525-30
12036884
Haematologica. 2001 Apr;86(4):399-403
11325646
Haematologica. 2006 Jan;91(1):133-6
16434383
Blood. 2008 Apr 15;111(8):3968-77
18245666
Cancer. 2003 Oct 15;98(8):1735-44
14534891
Blood. 2006 Oct 1;108(7):2165-72
16772605
Cancer. 2005 Oct 1;104(7):1428-33
16116606
Leuk Lymphoma. 2002 Sep;43(9):1777-82
12685831
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 May;103(5):599-609
17291793
J Dent Res. 2007 Nov;86(11):1022-33
17959891
Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6279s-6284s
17062714
Blood. 2002 Aug 15;100(4):1168-71
12149193
N Engl J Med. 2006 May 11;354(19):2079-80
16687729
J Clin Oncol. 2005 Dec 1;23(34):8580-7
16314620
Ann Hematol. 2003 Oct;82(10):654-9
12845480
Int J Radiat Oncol Biol Phys. 1993 Apr 2;25(5):801-4
7683017
N Engl J Med. 2005 Jul 7;353(1):99-102; discussion 99-102
16000365